Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
Dyne Therapeutics announced new preclinical data demonstrating that its FORCE platform can cross the blood-brain barrier and achieve robust knockdown of MAPT RNA in the central nervous systems of mice and nonhuman primates. The data features a modified conjugate optimized for CNS delivery, which achieved approximately 75% MAPT RNA knockdown and showed consistent delivery across brain regions including the deep brain.
Key figures
- Mapt knockdown conjugate 2
- approximately 75%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.